In a major breakthrough, Zydus Cadila has received approval for Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D on Friday, the world’s first and India’s indigenously developed DNA based vaccine for Covid-19 to be administered in children and adults 12 years and above.
Developed in partnership with the Department of Biotechnology, Government of India under the ‘Mission COVID Suraksha’ and implemented by BIRAC, ZyCoV-D has been supported under Covid-19 Research Consortia through National Biopharma Mission for Preclinical studies, Phase I and Phase II Clinical Trials and under the Mission COVID Suraksha for Phase III Clinical Trial.
"This three dose vaccine which when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from disease as well as viral clearance. The plug-and-play technology on which the plasmid DNA platform is based can be easily adapted to deal with mutations in the virus, such as those already occurring," said Ministry of Science & Technology in a statement.
Speaking on the development, Chairman of the Zydus Group, Pankaj R. Patel said, “We are extremely happy that our efforts to put out a safe, well tolerated and efficacious vaccine to fight Covid-19 has become a reality with ZyCoV-D. To create the world’s first DNA vaccine at such a crucial juncture and despite all the challenges, is a tribute to the Indian research scientists and their spirit of innovation.”
Meanwhile, Prime Minister Narendra Modi has said that the approval for world’s first DNA based ‘ZyCov-D’ vaccine of Zydus Universe is a testimony to the innovative zeal of India’s scientists.
In response to a tweet by CDSCO India Info, the Prime Minister said,"India is fighting Covid-19 with full vigour. The approval for world’s first DNA based ‘ZyCov-D’ vaccine of @ZydusUniverse is a testimony to the innovative zeal of India’s scientists. A momentous feat indeed."